A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.
about
The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastomaTargeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancerSequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway.Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.Pharmacologic inhibition of lactate production prevents myofibroblast differentiation.A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer.Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family membersA phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.Transgenic expression of the human MRP2 transporter reduces cisplatin accumulation and nephrotoxicity in Mrp2-null mice.Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.Recent advances in gossypol derivatives and analogs: a chemistry and biology view.(±)-Gossypol induces apoptosis and autophagy in head and neck carcinoma cell lines and inhibits the growth of transplanted salivary gland cancer cells in BALB/c mice.AT-101 inhibits hedgehog pathway activity and cancer growth.Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol.Present and future of cancer immunotherapy: A tumor microenvironmental perspective
P2860
Q26827928-004B22C8-9E64-4875-90FC-F5E47AE8DBD6Q30983828-B26A0C0F-2516-4A1A-89DF-C24BA7FF2ABBQ34742904-D0E4D52D-7C24-4660-B8AF-EBF30C06F17DQ35743521-ABC6320C-39CB-4B58-AA60-E97F0BFC58CBQ36345864-AA2D5527-7B93-4B1F-8BD4-A1C3B920DA09Q36421822-4EB67CBF-2B71-463C-8827-8772DFE30806Q36601134-ABFA1F08-7BB7-42F2-8B9F-88A7CE27622FQ37284056-6D3FE311-DAB5-49C5-AC2F-3D7A6937410DQ37734911-77FC9B6F-60FB-432D-A5FF-92802F75DEB0Q38442515-AA2529B7-DA44-4323-9541-A89813236EBBQ38655357-F5DBC801-39BC-4C53-8B79-12BD31A7A809Q38743654-F4B9B10F-073F-41C2-8652-4F27E16787ABQ38859894-301085DC-63B7-48D7-A4E4-F4B3922515EFQ55029093-9A839BA3-9A1D-4204-A137-3BE4EA8098D7Q57144510-BF809DEB-474A-4663-8E79-BFB8E9DC9073
P2860
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase I study of AT-101 with ...... -stage small cell lung cancer.
@en
A phase I study of AT-101 with ...... -stage small cell lung cancer.
@nl
type
label
A phase I study of AT-101 with ...... -stage small cell lung cancer.
@en
A phase I study of AT-101 with ...... -stage small cell lung cancer.
@nl
prefLabel
A phase I study of AT-101 with ...... -stage small cell lung cancer.
@en
A phase I study of AT-101 with ...... -stage small cell lung cancer.
@nl
P2093
P2860
P1476
A phase I study of AT-101 with ...... -stage small cell lung cancer.
@en
P2093
Anne M Traynor
Dona B Alberti
Jens Eickhoff
Jill M Kolesar
Michael Keppen
Naoko Takebe
Rebecca M Marnocha
Tabraiz A Mohammed
William R Schelman
P2860
P2888
P304
P356
10.1007/S10637-013-9999-7
P577
2013-07-17T00:00:00Z